Gerald R. Galluppi

3.2k citations

44 papers · 2.5k indexed · 3 hit papers · h-index 17

Molecular Biology top 5%
Cardiology and Cardiovascular Medicine top 5%
Plant Science top 5%
Biotechnology top 2%
Oncology top 10%

Co-authors: Ned R. Siegel Steven P. Adams John P. Richardson Shad R. Eubanks David M. Geller Mark G. Currie Barbara R. Cole Philip Needleman
Topics: Pharmaceutical studies and practices (7 papers)Receptor Mechanisms and Signaling (6 papers)DNA and Nucleic Acid Chemistry (5 papers)
Cited by: Biotechnology Molecular Biology Cardiology and Cardiovascular Medicine
Journals: Science Cell Proceedings of the National Academy of Sciences
Partner nations: United States Japan United Kingdom

In The Last Decade

Gerald R. Galluppi

43 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of bacterial genes in plant cells.

1983 524 citations Gerald R. Galluppi et al. profile →
Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta.

1986 470 citations Gerald R. Galluppi et al. profile →
Purification and Sequence Analysis of Bioactive Atrial Peptides (Atriopeptins)

1984 460 citations Gerald R. Galluppi et al. profile →

Peers

Countries citing papers authored by Gerald R. Galluppi

Since Specialization

Citations

This map shows the geographic impact of Gerald R. Galluppi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald R. Galluppi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald R. Galluppi more than expected).

Fields of papers citing papers by Gerald R. Galluppi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald R. Galluppi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald R. Galluppi. The network helps show where Gerald R. Galluppi may publish in the future.

Co-authorship network of co-authors of Gerald R. Galluppi

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald R. Galluppi. A scholar is included among the top collaborators of Gerald R. Galluppi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald R. Galluppi. Gerald R. Galluppi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I 2025 ·Diabetes Obesity and Metabolism ·(unknown),Robert Lew,(unknown),(unknown),Gerald R. Galluppi,Yu‐Luan Chen,Yongquan Lai,Manu V. Chakravarthy,(unknown),Kenneth S. Koblan,Seth C. Hopkins	0
2	Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program 2024 ·Clinical Pharmacology & Therapeutics ·Gerald R. Galluppi,Malidi Ahamadi,(unknown),Nageshwar Budha,Ferdous Gheyas,Chi‐Chung Li,Yuan Chen,Anne‐Gaëlle Dosne,Niels Rode Kristensen,Mindy Magee,Mahesh N. Samtani,Vikram Sinha,Kunal S. Taskar,Vijay Upreti,Jianning Yang,Jack Cook	6
3	A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia 2023 ·Clinical and Translational Science ·(unknown),Snežana Milanović,Börje Darpö,(unknown),(unknown),(unknown),(unknown),MaryAlice Worden,Seth C. Hopkins,Gerald R. Galluppi	7
4	A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects 2023 ·Clinical Pharmacokinetics ·(unknown),Yu‐Luan Chen,Guangqing Xiao,(unknown),Snežana Milanović,MaryAlice Worden,(unknown),(unknown),Seth C. Hopkins,Gerald R. Galluppi	4
5	Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans 2023 ·Neurology and Therapy ·Yu‐Luan Chen,(unknown),Snežana Milanović,Lei Shi,Yan Li,Yongcai Mao,Kenneth S. Koblan,Gerald R. Galluppi	4
6	In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia 2022 ·Pharmaceutical Research ·Guangqing Xiao,Yu‐Luan Chen,Nina Dedic,(unknown),Kenneth S. Koblan,Gerald R. Galluppi	11
7	A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study 2021 ·Journal of Pharmaceutical and Biomedical Analysis ·Yu‐Luan Chen,Yao Shi,(unknown),Lei Shi,Kenneth S. Koblan,Gerald R. Galluppi	7
8	The rate of dasotraline brain entry is slow following intravenous administration 2020 ·Psychopharmacology ·Robert Lew,Cristian Constantinescu,Daniel Holden,Richard E. Carson,Vincent M. Carroll,Gerald R. Galluppi,Kenneth S. Koblan,Seth C. Hopkins	2
9	Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease 2019 ·Respiratory Research ·Brian Leaker,Dave Singh,Grant C. Nicholson,(unknown),Thomas Goodin,Ayca Ozol-Godfrey,Gerald R. Galluppi,Peter J. Barnes	4
10	Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures 2018 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown),Elizabeth Ludwig,Jill Fiedler‐Kelly,Seth C. Hopkins,Gerald R. Galluppi,David Blum	8
11	Modeling and Simulation Strategy to Support Eslicarbazepine Acetate (ESL) Pediatric Dose Selection in the Treatment of Partial Onset Seizures Based on Matching Adult Exposures (P3.246) 2017 ·Neurology ·(unknown),(unknown),Seth C. Hopkins,Jill Fiedler‐Kelly,Elizabeth Ludwig,Gerald R. Galluppi,David Blum	1
12	Physiologically-Based and Population Pharmacokinetic Modeling and Simulation to Support Dose Selection and Study Design for Eslicarbazepine Acetate (ESL) Adjunctive Therapy in Infants with Partial Onset Seizures (POS) (P3.244) 2017 ·Neurology ·(unknown),Elizabeth Ludwig,(unknown),(unknown),Seth C. Hopkins,Gerald R. Galluppi,Jill Fiedler‐Kelly,David Blum	1
13	First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica 2015 ·PLoS ONE ·Paul Rolan,Gilmore O’Neill,Eve Versage,Jitesh Rana,Yongqiang Tang,Gerald R. Galluppi,Ernesto Aycardi	23
14	A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors 2014 ·Investigational New Drugs ·Margaret von Mehren,Carolyn D. Britten,(unknown),Wayne Saville,Artemios B. Vassos,Sarah Harris,Gerald R. Galluppi,Mohamed Darif,Zev A. Wainberg,Roger B. Cohen,Stephen Leong	16
15	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis 2013 ·Clinical Therapeutics ·Nicolas Wisniacki,Lakshmi Amaravadi,Gerald R. Galluppi,Timothy S. Zheng,Ray Zhang,Jessica Kong,Linda C. Burkly	53
16	Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors 2013 ·Clinical Cancer Research ·David S. Hong,Rabih Said,Gerald S. Falchook,Aung Naing,Stacy Moulder,Apostolia M. Tsimberidou,Gerald R. Galluppi,Naveen Dakappagari,Chris Storgard,Razelle Kurzrock,Lee S. Rosen	20
17	Plasma Protein Binding in Drug Discovery and Development 2010 ·Combinatorial Chemistry & High Throughput Screening ·Monique Howard,John J. Hill,Gerald R. Galluppi,Matthew A. McLean	122
18	Accelerating drug development: methodology to support first‐in‐man pharmacokinetic studies by the use of drug candidate microdosing 2007 ·Drug Development Research ·Matthew A. McLean,(unknown),(unknown),Christopher L. Holliman,R. M. J. Ings,Gerald R. Galluppi	8
19	Renaturation and Purification of Human Tissue Factor Pathway Inhibitor Expressed in Recombinant E. coli 1994 ·Protein Expression and Purification ·Mark E. Gustafson,Katrin Junger,Tze-Chein Wun,(unknown),(unknown),D. Welsch,Mark G. Obukowicz,(unknown),Gary S. Bild,Richard M. Leimgruber,Mark O. Palmier,(unknown),(unknown),Ronald B. Frazier,Gerald R. Galluppi,(unknown)	11
20	Nucleoside Triphosphate Requirement for Termination of RNA Synthesis by Rho Factor 1976 ·Cold Spring Harbor Monograph Archive ·Gerald R. Galluppi,(unknown),John P. Richardson	10

About Gerald R. Galluppi

Gerald R. Galluppi is a scholar working on Pediatrics, Perinatology and Child Health, Psychiatry and Mental health and Molecular Biology, having authored 44 papers that have together received 2.5k indexed citations. Recurring topics across this work include Pharmaceutical studies and practices (7 papers), Receptor Mechanisms and Signaling (6 papers) and DNA and Nucleic Acid Chemistry (5 papers). The work is most often cited by research in Biotechnology (270 citations), Molecular Biology (1.7k citations) and Cardiology and Cardiovascular Medicine (385 citations). Gerald R. Galluppi has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Ned R. Siegel, Steven P. Adams, John P. Richardson, Shad R. Eubanks, David M. Geller, Mark G. Currie, Barbara R. Cole, Philip Needleman, Kam F. Fok and Saeid M. Seyedin. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact